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activity of 10 and 11 was investigated in host cells and in parasites. Both compounds induced depolarization of mitochondrial membrane potential, upregulation of reactive oxygen species (ROS) levels and increased plasma membrane permeability in Leishmania parasites.
Immunomodulatory assays suggested an NO-independent effect of guanidines 10 and 11 on macrophages. The same compounds also promoted anti-inflammatory activity in L. (L.) infantuminfected macrophages co-cultived with splenocytes, reducing the production of cytokines MCP-1 and IFN-γ. Guanidines 10 and 11 affect the bioenergetic metabolism of Leishmania, with selective elimination of parasites via a host-independent mechanism. Considerable attention has been raised to address the effective cure of neglected tropical diseases (NTDs) in the last decade, which globally impact mainly economically disfavored nations. These infectious pathogenies, of which most have parasites as the causative agents, have spread and now affect population in developed countries as well. Most drugs to treat NTDs were developed decades ago and show harmful, even deadly, adverse effects. Therefore, the search for new drugs or vaccines to treat human neglected diseases is a priority for the World Health Organization and other organizations. 1, 2 Two of the deadliest NTDs are leishmaniasis and Chagas disease. Leishmaniasis affects 12 million people in 98 countries mainly in Africa, Asia, and Latin America. 3, 4 Two distinct human pathological conditions are observed for leishmaniasis, cutaneous and visceral.
Leishmania (L.) infantum is the etiologic agent of visceral leishmaniasis (VL) in South America
and southern Europe countries, while Leishmania (L.) donovani is in Asian and African countries. Visceral leishmaniasis promoted by L. (L.) infantum is fatal, with a mortality rate of 100% if untreated. 4 Leishmaniasis is included as a target disease by DNDi (Drugs for Neglected Diseases initiative) and iOWH (Institute for One World Health).
Chagas disease is caused by Trypanosoma cruzi as a potentially fatal disorder resulting in cardiomegaly and megacolon in about 30% of the patients. 5 Chagas disease remains one of the most severe public-health problems in 21 countries of Latin America, causing more than 7000 deaths per year without early and successful antiparasitic treatment. Over 25 million people are at risk of infection by T. cruzi and about 7 million people are infected worldwide. 1 Chagas disease has spread into several European countries and Japan, probably due to population migration.
Effective treatments for Chagas disease are urgently needed. Miltefosine and benznidazole were used as standard drugs and showed CC50 values of 122.0 µM and 469.9 µM, respectively ( Table 1) .
Immunomodulatory Potential of Compounds. Quantification of Nitric Oxide (NO).
Guanidines 10 and 11 showed the highest selectivity index (25 and 20, respectively) as antileishmanial agents (Table 1 , Selectivity Index), and were selected for further mechanism of action assays. Compounds 10 and 11 were incubated with peritoneal macrophages and the NO content was evaluated after 24 h. Both compounds revealed no capacity to upregulate NO production ( Figure 1 ). Bacterial lipopolysaccharide (LPS) was used as the positive control. 
Cellular

Among 18 guanidine compounds tested against T. cruzi trypomastigotes, 14 (77%)
showed activity bellow 100 µM, of which compounds 1, 5, 6, 7, 9, 11 and 17 presented IC50 values below 10 µM. Guanidines 5, 6, 7, and 9 showed low cytotoxicity and the highest selectivity indexes (SI), between 12 and 28. Guanidine 17 was approximately X-fold more effective than the standard drug benznidazole. Guanidines 6 and 7 were about 120-fold more effective, presenting a trypanocidal activity observed by the lack of mitochondrial activity measured by resazurin. Other guanidine compounds were tested against T. cruzi and showed potent activity, in the range between 1 and 10 µM, 13 similarly as observed for compounds 1, 5, 6, 7, 9, 11 and 17. Compound 17 displayed potent antitrypanosomal activity, with an IC50 value of 0.95 µM. However, the selectivity index was below 10, and cannot attend an important criteria for the hit stage.
Guanidine compounds isolated as natural products and synthetic derivatives have also shown potent antileishmanial activity. [14] [15] [16] [17] [18] Guanidines 10 and 11 presented SI of 25 and 20, respectively, and were selected for investigation of the lethal mechanism of action against Leishmania parasites.
Due to the complexity of intracellular amastigote defenses, an antileishmanial suitable hit compound needs to specifically target the parasite which lives in the acidic parasitophorous vacuole inside the macrophage. 21 Guanidines 10 and 11 showed more potent antiparasitic activity against intracellular amastigotes than to extracellular promastigotes. In order to investigate if the antileishmanial activity of 10 and 11 against intracellular amastigotes could be ascribed to an immunomodulatory effect in host cells, we evaluated cytokine production by macrophages in the presence of guanidines 10 and 11. This approach enables to differentiate compounds that are directly active in the parasite from those that exert antiparasitic effect by an immunomodulatory response. 22 Immunomodulators have been investigated as drugs for the clinical treatment of leishmaniasis, but with limited efficacy when administered alone. 23, 24 Guanidines 10 and 11
caused no upregulation of NO in macrophages. Flow cytometry analysis indicated that 10 and 11
significantly suppressed the production of IFN-γ and MCP-1 cytokines in the host cell, causing no significant alteration of TNF, IL-6 and IL-10 levels. Cytokines play different roles during a
treatment with monocyte chemotactic protein chemokine (MCP-1) enhances NO production and the antileishmanial activity. 25 MCP-1 is a leukocyte activator, related to the production of proinflammatory cytokines and microbicidal molecules. It promotes NO release and increased parasite killing by T. cruzi-infected macrophages. Upregulation of cytokine IL-6 has been associated with a lethal outcome of the disease, preceding death in patients with visceral leishmaniasis (VL). 26 High levels of IFN-γ, IL-10, and IL-6 are associated with human visceral leishmaniasis and with leishmaniasis persistence. 27, 28 In addition to the downregulation of inflammatory cytokines induced by guanidines 10 and 11 in Leishmania-infected macrophages co-cultived with splenocytes, both compounds promoted the death of intracellular amastigotes. Attenuation of immune response by immunomodulators, such as pentoxyfylline associated with pentavalent antimony, decrease tissue inflammation in patients, leading to a curative therapy associated with the decrease of TNF and IFN-γ levels. 29 These results suggest that guanidines 10 and 11 exert antileishmanial activity by a direct effect on parasites, promoting anti-inflammatory modulation in host cells, which might contribute to a beneficial prognosis of the disease.
Because the antileishmanial activity of guanidines 10 and 11 was associated to other mechanisms than merely macrophage activation, we investigated possible intracellular targets in
Leishmania. Damage to the plasma membrane and mitochondria was then evaluated using different fluorescent probes, as mitochondria are unique machinery in protozoan parasites and have been shown as a potential target for antiparasitic drugs. [30] [31] [32] [33] The permeability of the L. (L.)
infantum plasma membrane was observed using green-fluorescent nuclear and chromosome counter stain, which does not enter live cells and exhibits >500-fold fluorescence enhancement after binding nucleic acids. 34 Both guanidines 10 and 11 increased fluorescence levels, indicating the promotion of increased membrane permeabilization within 60 min of incubation.
The mitochondrial membrane potential is crucial for ATP generation in the respiratory chain. 33 In contrast to mammalian cells, where the presence of multiple mitochondria ensures compensation for functionally impaired ones, trypanosomatids present a single mitochondrion. 30 We investigated the effects of 10 and 11 on Leishmania mitochondria at initial contact. Both compounds 10 and 11 induced rapid depolarization of the mitochondrial membrane potential to levels similar to the positive control. Amphotericin B, used in the treatment of leishmaniasis, also increases permeability of the Leishmania plasma membrane, followed by a rapid decrease in the mitochondrial membrane potential. 35 Paromomycin significantly decreases the mitochondrial membrane potential of Leishmania, indicating that this organelle might be the ultimate drug target.
31,32
Leishmania parasites present various defense mechanisms to cope with oxidative stress, including expression of antioxidant enzymes such as trypanothione (T(SH)2), 36 superoxide dismutase, 37 peroxidases, 38 trypanothione S-transferase 39 and 6-phosphogluconate dehydrogenase (6PGDH). 40 These enzymes, including iron superoxide dismutase and peroxiredoxin, are located in the mitochondria. 41 During oxidative stress, excessive amounts of reactive oxygen species supplemented with 10% fetal calf serum at 37 ºC in 5% CO2-humidified incubator.
Determination of the 50% Inhibitory Concentration (IC50). Promastigotes: Promastigotes in
late growth-phase (non-stationary at 3 x 10 7 /mL, passage 5) were counted in a hemocytometer chamber and seeded at 1 x 10 6 /well, with a final volume of 150 µL. The compounds were dissolved in DMSO and diluted in M-199 medium in 96-well microplates, with the highest concentration of 150 µM for 48 h at 24 ºC. The parasite viability was determined using the MTT colorimetric assay. 53 The optical density was read at 570 nm (FilterMax F5 Multi-Mode Microplate Reader, Molecular Devices) using control wells without drugs (100% viability) and without cells (blank). The control group consisted of promastigotes incubated with 0.5% DMSO.
Miltefosine was used as a standard drug. Compounds were tested to the highest concentration of Amastigotes: Peritoneal macrophages were collected from the peritoneal cavity of BALB/c mice, and the macrophages were seeded at 1 x 10 5 /well for 24 h in a 16-well slide. Amastigotes were prepared as described previously in a 1:10 ratio of macrophages to amastigotes for 24 h at 37 ºC 5% CO2-humidified incubator. The compounds were incubated with infected macrophages for 120 h. Miltefosine was used as standard drug. Subsequently, the cells were fixed with MeOH, stained with Giemsa and observed using a light microscope. The parasite burden was determined by the number of infected macrophages out of 400 cells. 20 Compounds were tested to the highest concentration of 100 µM and were reported as NA (not active) when the IC50 value was above this concentration. CO2-humidified incubator. The parasite viability was determined using the resazurin (0.011% in PBS). 54 The optical density was read at 570 nm using control wells without drugs (100% viability) and without cells (blank). The control group consisted of trypomastigotes incubated with 0.5% DMSO. Benznidazole was used as a standard drug. Compounds were tested to the highest concentration of 100 µM and were reported as NA (not active) when the IC50 value was above this concentration.
Trypomastigotes of
Cytotoxicity in Mammalian Cells. NCTC cells were counted in a hemocytometer chamber, seeded at 6 x 10 4 /well and incubated in highest concentrations to 150 μM for 48 h at 37 o C in a 5% CO2-humidified incubator. The cell viability was determined using the MTT assay. 53 Miltefosine was used as standard drug. The selectivity index (SI) was determined using the relationship, CC50 against NCTC/IC50 against parasites. 7 /mL, passage 7) promastigotes were washed in PBS, seeded at 2 x 10 6 /well and incubated with 1 µM SYTOX Green for 15 min at 24 o C. 34 The compounds 
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